Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer (2015) 2.67

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Class B Cirrhosis (C-SALT Part A)• Ledipasvir/Sofosbuvir With Ribavirin Is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients With HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial• Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks• Sofosbuvir + Peginterferon/Ribavirin for 12 Weeks Vs Sofosbuvir + Ribavirin for 16 or 24 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study• Safety and Efficacy of the Combination Daclatasvir-Sofosbuvir in HCV Genotype 1-Mono-Infected Patients From the French Observational Cohort ANRS CO22 HEPATHER• C-SWIFT: Grazoprevir/Elbasvir + Sofosbuvir in Cirrhotic and Noncirrhotic, Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection for Durations of 4, 6 or 8 Weeks and Genotype 3 Infection for Durations of 8 or 12 WeeksPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MD Chief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois. Gastroenterol Hepatol (N Y) (2015) 2.20

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet (2015) 2.18

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 2.17

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07

Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. Open Forum Infect Dis (2014) 2.06

Hepatitis C. Lancet (2015) 1.95

An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on:• SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/R/ABT-267, ABT-333, and Ribavirin in Treatment-Experienced Adults With Hepatitis C Virus Genotype 1• All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study• PEARL-III: 12 Weeks of ABT-450/R/267 + ABT-333 Achieved SVR in >99% of 419 Treatment-Naive HCV Genotype 1B-Infected Adults With or Without Ribavirin• Results of the Phase 2 Study M12-999: Interferon-Free Regimen of ABT-450/R/ABT-267 + ABT-333 + Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection• Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety• All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1B Infection: Phase 3 Study Results• Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including Genotype-3 Patients, Decompensated Genotype-1 Patients, and Genotype-1 Patients With Prior Sofosbuvir Treatment Experience• Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter StudyPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MDChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois. Gastroenterol Hepatol (N Y) (2014) 1.27

Cost-effectiveness of screening for hepatitis C in Canada. CMAJ (2015) 1.16

Treatment Options in Hepatitis C. Dtsch Arztebl Int (2017) 1.10

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology (2016) 1.10

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. J Clin Exp Hepatol (2016) 1.02

No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL. Hepatology (2015) 1.01

Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol (2014) 1.00

Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol (2015) 0.99

Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res (2015) 0.99

Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol (2014) 0.98

Advances in hepatitis C therapy: What is the current state - what come's next? World J Hepatol (2016) 0.98

Chronic hepatitis C: This and the new era of treatment. World J Hepatol (2016) 0.98

Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. P T (2015) 0.98

The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol (2015) 0.97

Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Hepatology (2015) 0.97

Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med (2015) 0.97

APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int (2016) 0.96

Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. Clin Infect Dis (2015) 0.96

Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med (2014) 0.95

Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep (2015) 0.94

Changing the face of hepatitis C management - the design and development of sofosbuvir. Drug Des Devel Ther (2015) 0.93

Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology (2016) 0.93

A SPECIAL MEETING REVIEW EDITION: Highlights in the Treatment of Hepatitis C Virus From the 2014 Liver Meeting: A Review of Selected Presentations From the 2014 Liver Meeting November 7-11, 2014 • Boston, MassachusettsSpecial Reporting on:• Evaluation of Sofosbuvir and Simeprevir-Based Regimens in the TRIO Network• Safety and Efficacy of New DAA-Based Therapy for Hepatitis C Post-Transplant: Interval Results From the HCV-TARGET Longitudinal, Observational Study• Efficacy and Safety of MK-5172 and MK-8742 ± Ribavirin in Hepatitis C Genotype 1 Infected Patients With Cirrhosis or Previous Null Response: Final Results of the C-WORTHY Study (Parts A & B)• Safety and Efficacy of Sofosbuvir in Combination With Simeprevir + Ribavirin in Patients With Genotype 1: Interim Results of a Prospective, Observational Study• All-Oral Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/BMS-791325, ± Ribavirin, for Patients With Chronic HCV Genotype 1 Infection and Compensated Cirrhosis: UNITY-2 Phase 3 SVR-12 Results• TURQUOISE-II: Regimens of ABT-450/R/Ombitasvir and Dasabuvir With Ribavirin Achieve High SVR12 Rates in HCV Genotype 1-Infected Patients With Cirrhosis, Regardless of Baseline CharacteristicsPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDChief of the Division of Gastroenterology and HepatologyVincent Astor Distinguished Professor of MedicineWeill Cornell Medical CollegeAttending PhysicianNewYork-Presbyterian HospitalNew York, New York. Gastroenterol Hepatol (N Y) (2014) 0.92

Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade. PLoS One (2015) 0.92

Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance. Viruses (2015) 0.92

The new era of hepatitis C virus therapy. Saudi J Gastroenterol (2015) 0.91

Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol (2015) 0.91

Beyond the NIH Multicenter HIV Transplant Trial Experience: Outcomes of HIV+ Liver Transplant Recipients Compared to HCV+ or HIV+/HCV+ Coinfected Recipients in the United States. Clin Infect Dis (2015) 0.90

HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. J Hepatol (2016) 0.90

Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. Am J Gastroenterol (2015) 0.89

Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat Rev Gastroenterol Hepatol (2016) 0.88

Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. World J Hepatol (2015) 0.88

Update on hepatitis C: Direct-acting antivirals. World J Hepatol (2015) 0.88

Sofosbuvir, a Significant Paradigm Change in HCV Treatment. J Clin Transl Hepatol (2015) 0.88

New treatment strategies for hepatitis C infection. World J Hepatol (2015) 0.88

Ledipasvir with sofosbuvir. Aust Prescr (2015) 0.88

Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol (2015) 0.87

Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent. PLoS One (2015) 0.87

New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y) (2015) 0.86

Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. Infect Dis Ther (2016) 0.86

Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. Pharmgenomics Pers Med (2014) 0.86

Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol (2015) 0.86

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. PLoS One (2015) 0.86

Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review. J Clin Transl Hepatol (2015) 0.86

Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon (2016) 0.86

SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol (2016) 0.85

High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatol Int (2015) 0.84

Modelling hepatitis C therapy--predicting effects of treatment. Nat Rev Gastroenterol Hepatol (2015) 0.84

Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. Clin Infect Dis (2015) 0.84

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. PLoS One (2014) 0.84

Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators Inflamm (2016) 0.83

Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase. Int J Mol Sci (2015) 0.83

An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens. Am J Gastroenterol (2016) 0.83

CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults. Can J Infect Dis Med Microbiol (2015) 0.83

Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection. Am Health Drug Benefits (2015) 0.83

Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/Ritonavir. Antimicrob Agents Chemother (2015) 0.83

Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens. AIDS Patient Care STDS (2015) 0.83

Cancers in Australia in 2010 attributable to infectious agents. Aust N Z J Public Health (2015) 0.83

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV). Adv Ther (2015) 0.83

Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology (2016) 0.82

Hepatitis C Associated B-cell Non-Hodgkin Lymphoma: Clinical Features and the Role of Antiviral Therapy. J Clin Transl Hepatol (2015) 0.82

Hepatitis C: Treatment triumphs. Nature (2014) 0.82

Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1. Medicine (Baltimore) (2016) 0.82

Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance. Viruses (2015) 0.82

Oncogenes and RNA splicing of human tumor viruses. Emerg Microbes Infect (2014) 0.82

Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial. Infect Dis Ther (2016) 0.81

Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies. N Am J Med Sci (Boston) (2016) 0.81

Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection. World J Virol (2015) 0.81

All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality. World J Hepatol (2015) 0.81

New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral Hepat (2016) 0.81

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. Gastroenterology (2016) 0.81

Recent advances in management of the HIV/HCV coinfected patient. Future Virol (2016) 0.81

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir. J Investig Med High Impact Case Rep (2015) 0.81

Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. Ann Gastroenterol (2016) 0.81

The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med (2015) 0.81

Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J Gastroenterol (2016) 0.81

Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother (2016) 0.81

New era for management of chronic hepatitis C virus using direct antiviral agents: A review. J Adv Res (2014) 0.80

Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies. World J Gastroenterol (2015) 0.80

Hepatitis C Infection in the Elderly. Dig Dis Sci (2015) 0.80

Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. World J Gastroenterol (2015) 0.80

The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing. Can J Gastroenterol Hepatol (2015) 0.80

Prisoners treated for hepatitis C with protease inhibitor, New York, USA, 2012. Emerg Infect Dis (2015) 0.80

Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline. Can J Gastroenterol Hepatol (2014) 0.80

Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value Health (2016) 0.80

Hepatitis C virus: Promising discoveries and new treatments. World J Gastroenterol (2016) 0.80

Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis. PLoS One (2015) 0.79

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int (2016) 0.79

Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. Hepatology (2015) 0.79

Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA. J Clin Microbiol (2015) 0.79

Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada. Can J Gastroenterol Hepatol (2015) 0.79

Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol (2016) 0.79

Genome sequence of the human malaria parasite Plasmodium falciparum. Nature (2002) 37.89

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47

The genome sequence of the malaria mosquito Anopheles gambiae. Science (2002) 20.36

Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01

Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99

Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30

Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07

Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45

Comparative genome and proteome analysis of Anopheles gambiae and Drosophila melanogaster. Science (2002) 9.43

Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49

Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet (2010) 6.52

Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44

Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14

Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med (2013) 6.08

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90

Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90

Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature (2010) 4.64

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27

Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med (2009) 4.21

Disparities in liver transplantation before and after introduction of the MELD score. JAMA (2008) 4.10

Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med (2014) 4.09